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background:  The clinical effect of thrombus aspiration (TA) during primary percutaneous coronary intervention (PPCI) is uncertain. The 
aim of our investigation was to assess long-term clinical outcomes of thrombus aspiration during PPCI.
methods:  A total of 619 patients were enrolled in Chonbuk National University hospital from 2008 January to 2012 February. 155 (25%) 
patients who underwent TA during PPCI was compared with 464 (75%) patients who were underwent PPCI without TA. MACE was defined 
as cardiac death, non-fatal myocardial infarction (MI), stent thrombosis and repeated revascularization (TVR).
Results:  Clinical outcomes at 3-years of overall enrolled patients were evaluated. There was no significant difference in MACE [TA (+) vs. 
TA (-); 29 (19%) vs 74 (16%), p=0.24]. Cardiac death [TA (+) vs. TA (-); 18 (11.6%) vs 49 (10.5%), p=0.40], MI [TA (+) vs. TA (-); 9 (5.8%) 
vs 23 (4.9%), p=0.40], TVR [TA (+) vs. TA (-); 15 (9.6%) vs 31 (6.7%), p=0.21] and stent thrombosis [TA (+) vs. TA (-); 5 (3.2%) vs 6 (1.3%), 
p=0.39] were not significantly different between the two groups (table). In a Cox-regression analysis, TA were not independent predictor of 
MACE (OR 1.219, p = 0.421, 95% CI 0.753-1.974). 
conclusion:  Thromus aspiration during PPCI as compared with PPCI alone did not improve the long-term clinical outcomes. Future larger 
studies are needed to clarify our results. 
TA (-)
(n = 464)
TA (+)
(n = 155) p-value
Total major adverse events, n (%) 74 (16%) 29 (19%) 0.248
Cardiac death, n (%) 49 (10.5%) 18 (11.6%) 0.407
Myocardial infarction, n
(%) 23 (4.9%) 9 (5.8%) 0.408
Repeat revascularization,
n (%) 31 (6.7%) 15 (9.6%) 0.219
Stent thrombosis, n (%) 6 (1.3%) 5 (3.2%) 0.390
